Marinus Pharma

Important Update: Marinus is Now Immedica Pharma US Inc. ? As part of the recent acquisition, Marinus Pharmaceuticals has officially changed its name to Immedica Pharma US Inc. This marks an exciting new chapter as we fully integrate into Immedica Pharma, a global organization dedicated to rare diseases and specialty care. ? With this transition, the Marinus LinkedIn page will soon be deactivated, but you can continue to stay updated by following Immedica Pharma AB for news, insights, and updates. ? We want to thank everyone who has engaged with us here over the years—your support has been invaluable. We look forward to continuing this journey as Immedica Pharma US Inc. ? ?? Follow Immedica here: Immedica Pharma AB

We are pleased to share that Immedica Pharma AB has officially completed its acquisition of Marinus. This milestone marks a significant step forward in our mission to advance treatments for people living with epilepsy and other serious neurological disorders. Thank you to our employees, partners, and—most importantly—the patients who inspire us every day. We look forward to this next chapter as part of Immedica. Further details, including important information for shareholders, can be found here:?https://lnkd.in/e4yxB2Yc

Genetic testing can help patients receive appropriate clinical management for their specific conditions. Learn more about the benefits of a confirmed genetic diagnosis for refractory seizures.

Stop by our booth at the American Epilepsy Society Conference to learn more about CDKL5 deficiency disorder and discuss treatment options for those impacted by this rare genetic epilepsy disorder.

Our team had an incredible experience at the annual Epilepsy Awareness Day presented by Sofie's Journey at Disneyland! We engaged with epilepsy physicians and patients to raise awareness about the vital needs and services available to the community. Check out the photos!

Today, we reported our Q3 2024 earnings and business updates. Learn more in our press release: https://lnkd.in/eg7XGRHh

Today, we shared topline results from our Phase 3 TrustTSC trial. Read more in our press release: https://lnkd.in/eqQAegfy We sincerely appreciate the patients, investigators, clinical sites and collaborators who supported and participated in this trial.

At just under a year old, Judith was diagnosed with CDKL5 deficiency disorder, a rare, X-linked DEE characterized by early-onset, refractory seizures and severe global developmental impairment. A special thank you to Medical Stories for bringing Judith’s story to light and promoting awareness of this rare disease. Watch the full episode, which is also airing via the PBS local stations, to learn more. https://lnkd.in/epJT7FkT

We recently hosted our virtual “PetOberfest” event where employees shared adorable photos of their pets and even brought some furry friends on camera to raise money for Canine Partners for Life! We’re proud to support this incredible organization and its mission to create life-changing partnerships with service and companion dogs, bringing independence and greater quality of life to those they work with, including individuals with epilepsy.?Here are some photos!

Today, we presented data from our pivotal Phase 3 RAISE trial in refractory status epilepticus at the Neurocritical Care Society Annual Meeting. Learn more in our press release: https://lnkd.in/ebHVx8KA